Oncología Traslacional
ONCTRAS
Netherlands Cancer Institute
Amsterda, HolandaNetherlands Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (11)
2024
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
2023
-
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Gynecologic Oncology, Vol. 178, pp. 119-129
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Obstetrical and Gynecological Survey
2021
-
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 12, pp. 1721-1731
-
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 5, pp. 632-642
-
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Gynecologic Oncology, Vol. 163, Núm. 1, pp. 41-49
2020
-
Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial
Journal of Clinical Oncology, Vol. 38, Núm. 30, pp. 3528-3537
2019
-
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087
-
Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
2018
-
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 379, Núm. 26, pp. 2495-2505